🚀 VC round data is live in beta, check it out!
Bioventus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bioventus and similar public comparables like Alpha Tau Medical, Synektik, Sunmax Biotechnology, MedicalSystem Technology and more.
Bioventus Overview
About Bioventus
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Founded
2015
HQ
Employees
930
Website
Financials (LTM)
EV
$951M
Bioventus Financials
Bioventus reported last 12-month revenue of $579M and EBITDA of $118M.
In the same LTM period, Bioventus generated $405M in gross profit, $118M in EBITDA, and $60M in net income.
Revenue (LTM)
Bioventus P&L
In the most recent fiscal year, Bioventus reported revenue of $568M and EBITDA of $116M.
Bioventus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $579M | XXX | $568M | XXX | XXX | XXX |
| Gross Profit | $405M | XXX | $388M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $118M | XXX | $116M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $60M | XXX | $59M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 10% | XXX | XXX | XXX |
| Net Debt | — | — | $243M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bioventus Stock Performance
Bioventus has current market cap of $708M, and enterprise value of $951M.
Market Cap Evolution
Bioventus' stock price is $10.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $951M | $708M | 0.0% | XXX | XXX | XXX | $0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioventus Valuation Multiples
Bioventus trades at 1.6x EV/Revenue multiple, and 8.1x EV/EBITDA.
EV / Revenue (LTM)
Bioventus Financial Valuation Multiples
As of April 20, 2026, Bioventus has market cap of $708M and EV of $951M.
Equity research analysts estimate Bioventus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bioventus has a P/E ratio of 11.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $708M | XXX | $708M | XXX | XXX | XXX |
| EV (current) | $951M | XXX | $951M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBIT | 12.4x | XXX | 12.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| P/E | 11.8x | XXX | 12.1x | XXX | XXX | XXX |
| EV/FCF | 12.7x | XXX | 13.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bioventus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bioventus Margins & Growth Rates
Bioventus' revenue in the last 12 month grew by 7%.
Bioventus' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.4M for the same period.
Bioventus' rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bioventus' rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bioventus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bioventus Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioventus | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Tau Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Synektik | XXX | XXX | XXX | XXX | XXX | XXX |
| Sunmax Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| MedicalSystem Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| SD Biosensor | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioventus M&A Activity
Bioventus acquired XXX companies to date.
Last acquisition by Bioventus was on XXXXXXXX, XXXXX. Bioventus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bioventus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioventus Investment Activity
Bioventus invested in XXX companies to date.
Bioventus made its latest investment on XXXXXXXX, XXXXX. Bioventus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bioventus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bioventus
| When was Bioventus founded? | Bioventus was founded in 2015. |
| Where is Bioventus headquartered? | Bioventus is headquartered in United States. |
| How many employees does Bioventus have? | As of today, Bioventus has over 930 employees. |
| Who is the CEO of Bioventus? | Bioventus' CEO is Robert E. Claypoole. |
| Is Bioventus publicly listed? | Yes, Bioventus is a public company listed on Nasdaq. |
| What is the stock symbol of Bioventus? | Bioventus trades under BVS ticker. |
| When did Bioventus go public? | Bioventus went public in 2021. |
| Who are competitors of Bioventus? | Bioventus main competitors are Alpha Tau Medical, Synektik, Sunmax Biotechnology, MedicalSystem Technology. |
| What is the current market cap of Bioventus? | Bioventus' current market cap is $708M. |
| What is the current revenue of Bioventus? | Bioventus' last 12 months revenue is $579M. |
| What is the current revenue growth of Bioventus? | Bioventus revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Bioventus? | Current revenue multiple of Bioventus is 1.6x. |
| Is Bioventus profitable? | Yes, Bioventus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bioventus? | Bioventus' last 12 months EBITDA is $118M. |
| What is Bioventus' EBITDA margin? | Bioventus' last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Bioventus? | Current EBITDA multiple of Bioventus is 8.1x. |
| What is the current FCF of Bioventus? | Bioventus' last 12 months FCF is $75M. |
| What is Bioventus' FCF margin? | Bioventus' last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Bioventus? | Current FCF multiple of Bioventus is 12.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.